366 related articles for article (PubMed ID: 31266353)
1. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
2. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
3. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
[TBL] [Abstract][Full Text] [Related]
5. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
6. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
Loo LS; Ailani J; Schim J; Baygani S; Hundemer HP; Port M; Krege JH
J Headache Pain; 2019 Jul; 20(1):84. PubMed ID: 31340760
[TBL] [Abstract][Full Text] [Related]
8. Lasmiditan in patients with common migraine comorbidities: a
Clemow DB; Baygani SK; Hauck PM; Hultman CB
Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
[TBL] [Abstract][Full Text] [Related]
10. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.
Lipton RB; Baygani SK; Tepper SJ; Krege JH; Vasudeva R; Pearlman EM; Hauck PM; Loo LS
J Headache Pain; 2021 Aug; 22(1):101. PubMed ID: 34454420
[TBL] [Abstract][Full Text] [Related]
11. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
Martin VT; Ahmed Z; Hochstetler HM; Baygani SK; Dong Y; Hauck PM; Khanna R
Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
[TBL] [Abstract][Full Text] [Related]
14. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
[TBL] [Abstract][Full Text] [Related]
15. Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain.
Peres MFP; Vasudeva R; Baygani SK; Dennehy EB; Vincent M; Friedman DI
Curr Med Res Opin; 2021 Jun; 37(6):1031-1038. PubMed ID: 33784930
[TBL] [Abstract][Full Text] [Related]
16. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
Tepper SJ; Krege JH; Lombard L; Asafu-Adjei JK; Dowsett SA; Raskin J; Buchanan AS; Friedman DI
Headache; 2019 Jul; 59(7):1052-1062. PubMed ID: 31152441
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
MacGregor EA; Komori M; Krege JH; Baygani S; Vincent M; Pavlovic J; Igarashi H
Cephalalgia; 2022 Dec; 42(14):1467-1475. PubMed ID: 35979677
[TBL] [Abstract][Full Text] [Related]
19. Migraine history and response to lasmiditan across racial and ethnic groups.
Charleston L; Savage-Edwards B; Bragg SM; Baygani SK; Dennehy EB
Curr Med Res Opin; 2022 May; 38(5):721-730. PubMed ID: 35350937
[TBL] [Abstract][Full Text] [Related]
20. The Effect and Safety of 5-HT
Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
